Maxi-Fen-20 by Maxtreme Pharma

Maxtreme Pharma is the company that makes the drug Maxi-Fen-20. It is an anti-oestrogenic drug that can be taken to treat female breast cancer.

Tamoxifen Citrate, also known as Nolvadex, is the drug's active component and is a member of the class of drugs known as selective oestrogen receptor modulators (SERMs).

Men frequently use this drug to restore their natural hormone levels and lessen negative effects following a cycle of steroid use.

The main advantages of Tamoxifen

Tamoxifen is one of the most well-liked anti-oestrogen drugs for post-cycle therapy (PCT), which is a procedure required after a cycle of anabolic steroids in order to restore the body's normal functions.

Restoring natural testosterone production and lessening the effects of oestrogen are two of the key objectives of PCT. By preventing oestrogen receptors in the body, Tamoxifen effectively contributes to both of these effects.

Men can prevent oestrogenic side effects including the feared gynecomastia (man boobs) and fluid accumulation by limiting the action of oestrogen on the body. Additionally, Tamoxifen raises good cholesterol while lowering bad cholesterol in the body.

Methods for taking Tamoxifen

Tamoxifen by Maxtreme Pharma is often taken in doses of 20–40 mg (1-2 tablets) per day for post-cycle therapy. PCT usually lasts between two and four weeks, depending on the drugs used and the length of the cycle.

Tamoxifen should be used at a lower dosage of no more than 10-20mg (half to one tablet) every day throughout the cycle to prevent negative effects during the steroid cycle.

Since Tamoxifen will have progestogenic adverse effects, it should not be used during or after cycles containing drugs like Nandrolone, Trenbolone, or Oxymetholone (Anadrol).

Side effects of Tamoxifen

Tamoxifen taken more than the advised dose may reduce the effects of steroids or boost the body's response to oestrogen.

When a drug is taken incorrectly, side effects can include:

• Headaches.
• Loss of appetite.
• Impaired vision.